NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/06/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9,886.39 mln
Float117 mln
Earnings Date08/06/2026
EPS
2.85
Stretched
P / E
30.09
Overvalued
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-1.9
Caution advised
1-Year Forecast
86.89
Fairly priced
Relative Strength
79
/ 100
Strongly outperforming
Business Description
Halozyme Therapeutics is a biopharmaceutical company based in San Diego, California, that develops a proprietary enzyme technology enabling drugs to be delivered by injection just beneath the skin rather than through a vein. This approach, built around its patented rHuPH20 enzyme, is licensed to many of the world's leading pharmaceutical companies and supports a wide range of treatments for conditions including cancer, multiple sclerosis, and autoimmune diseases. Founded in 1998, the company operates across the United States and several international markets, generating revenue primarily through its partnerships and licensing agreements rather than direct drug sales.